

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

July 14, 2011

<u>Via E-mail</u> Dr. Mark J. Pykett President and Chief Executive Officer Neoprobe Corporation 425 Metro Place North Dublin, OH 43017

> Re: Neoprobe Corporation Preliminary Proxy Statement on Schedule 14A Filed June 14, 2011 File No. 001-35076

Dear Dr. Pykett:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Daniel Morris for

Amanda Ravitz Assistant Director

cc (via E-Mail):

Brett P. Thornton, Esq. – Porter, Wright, Morris & Arthur LLP